SEARCH

SEARCH BY CITATION

References

  • Admiraal PJ, Derkx FH, Danser AH, Pieterman H & Schalekamp MA (1990). Metabolism and production of angiotensin I in different vascular beds in subjects with hypertension. Hypertension 15, 4455.
  • Allred AJ, Diz DI, Ferrario CM & Chappell MC (2000). Pathways for angiotensin-(1–7) metabolism in pulmonary and renal tissues. Am J Physiol Renal Physiol 279, F841F850.
  • Anderson S, Rennke HG & Brenner BM (1986). Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat. J Clin Invest 77, 19932000.
  • Bos H, Laverman GD, Henning RH, Tiebosch AT, De Jong PE, De Zeeuw D & Navis G (2003). Involvement of renal ACE activity in proteinuria-associated renal damage in untreated and treated adriamycin nephrotic rats. J Renin Angiotensin Aldosterone Syst 4, 106112.
  • Campbell DJ, Lawrence AC, Towrie A, Kladis A & Valentijn AJ (1991). Differential regulation of angiotensin peptide levels in plasma and kidney of the rat. Hypertension 18, 763773.
  • Chappell MC, Pirro NT, Sykes A & Ferrario CM (1998). Metabolism of angiotensin-(1–7) by angiotensin-converting enzyme. Hypertension 31, 362367.
  • Dzau VJ, Bernstein K, Celermajer D, Cohen J, Dahlof B, Deanfield J, Diez J, Drexler H, Ferrari R, Van Gilst W, Hansson L, Hornig B, Husain A, Johnston C, Lazar H, Lonn E, Luscher T, Mancini J, Mimran A, Pepine C, Rabelink T, Remme W, Ruilope L, Ruzicka M, Schunkert H, Swedberg K, Unger T, Vaughan D & Weber M (2001). The relevance of tissue angiotensin-converting enzyme: manifestations in mechanistic and endpoint data. Am J Cardiol 88, 1L20L.
  • Ferrario CM & Iyer SN (1998). Angiotensin-(1–7): a bioactive fragment of the renin-angiotensin system. Regul Pept 78, 1318.
  • Ferrario CM, Jessup J, Chappell MC, Averill DB, Brosnihan KB, Tallant EA, Diz DI & Gallagher PE (2005a). Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. Circulation 111, 26052610.
  • Ferrario CM, Jessup J, Gallagher PE, Averill DB, Brosnihan KB, Ann Tallant E, Smith RD & Chappell MC (2005b). Effects of renin-angiotensin system blockade on renal angiotensin-(1–7) forming enzymes and receptors. Kidney Int 68, 21892196.
  • Fox J, Guan S, Hymel AA & Navar LG (1992). Dietary Na and ACE inhibition effects on renal tissue angiotensin I and II and ACE activity in rats. Am J Physiol Renal Physiol 262, F902F909.
  • Gembardt F, Sterner-Kock A, Imboden H, Spalteholz M, Reibitz F, Schultheiss HP, Siems WE & Walther T (2005). Organ-specific distribution of ACE2 mRNA and correlating peptidase activity in rodents. Peptides 26, 12701277.
  • The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia) (1997). Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 349, 18571863.
  • Hirsch AT, Talsness CE, Schunkert H, Paul M & Dzau VJ (1991). Tissue-specific activation of cardiac angiotensin converting enzyme in experimental heart failure. Circ Res 69, 475482.
  • Huang W, Gallois Y, Bouby N, Bruneval P, Heudes D, Belair MF, Krege JH, Meneton P, Marre M, Smithies O & Alhenc-Gelas F (2001). Genetically increased angiotensin I-converting enzyme level and renal complications in the diabetic mouse. Proc Natl Acad Sci U S A 98, 1333013334.
  • Igase M, Strawn WB, Gallagher PE, Geary RL & Ferrario CM (2005). Angiotensin II AT1 receptors regulate ACE2 and angiotensin-(1–7) expression in the aorta of spontaneously hypertensive rats. Am J Physiol Heart Circ Physiol 289, H1013H1019.
  • Ingert C, Grima M, Coquard C, Barthelmebs M & Imbs JL (2002). Effects of dietary salt changes on renal renin-angiotensin system in rats. Am J Physiol Renal Physiol 283, F9951002.
  • Iyer SN, Chappell MC, Averill DB, Diz DI & Ferrario CM (1998). Vasodepressor actions of angiotensin-(1–7) unmasked during combined treatment with lisinopril and losartan. Hypertension 31, 699705.
  • Jessup J, Gallagher PE, Averill DB, Brosnihan KB, Tallant EA, Chappell M & Ferrario CM (2006). Effect of angiotensin II blockade on a new congenic model of hypertension derived from transgenic Ren-2 rats. Am J Physiol Heart Circ Physiol 291, H2166H2172.
  • Kocks MJ, Lely AT, Boomsma F, De Jong PE & Navis G (2005). Sodium status and angiotensin-converting enzyme inhibition: effects on plasma angiotensin-(1–7) in healthy man. J Hypertens 23, 597602.
  • Kohara K, Brosnihan KB, Chappell MC, Khosla MC & Ferrario CM (1991). Angiotensin-(1–7). A member of circulating angiotensin peptides. Hypertension 17, 131138.
  • Kohara K, Brosnihan KB & Ferrario CM (1993). Angiotensin(1–7) in the spontaneously hypertensive rat. Peptides 14, 883891.
  • Konoshita T, Wakahara S, Mizuno S, Motomura M, Aoyama C, Makino Y, Kawai Y, Kato N, Koni I, Miyamori I & Mabuchi H (2006). Tissue gene expression of renin-angiotensin system in human type 2 diabetic nephropathy. Diabetes Care 29, 848852.
  • Krikken JA, Lely AT, Bakker SJ & Navis G (2007). The effect of a shift in sodium intake on renal hemodynamics is determined by body mass index in healthy young men. Kidney Int 71, 260265.
  • Largo R, Gomez-Garre D, Soto K, Marron B, Blanco J, Gazapo RM, Plaza JJ & Egido J (1999). Angiotensin-converting enzyme is upregulated in the proximal tubules of rats with intense proteinuria. Hypertension 33, 732739.
  • Luque M, Martin P, Martell N, Fernandez C, Brosnihan KB & Ferrario CM (1996). Effects of captopril related to increased levels of prostacyclin and angiotensin-(1–7) in essential hypertension. J Hypertens 14, 799805.
  • Marleau S, Ong H, Brochu M, Yamaguchi N, De Lean A & Du Souich P (1990) Endogenous atrial natriuretic factor after endopeptidase 24.11 inhibition by Thiorphan. Peptides 11, 378391.
  • Mento PF & Wilkes BM (1987). Plasma angiotensins and blood pressure during converting enzyme inhibition. Hypertension 9, III42III48.
  • Moriguchi A, Brosnihan KB, Kumagai H, Ganten D & Ferrario CM (1994). Mechanisms of hypertension in transgenic rats expressing the mouse Ren−2 gene. Am J Physiol 266, R1273R1279.
  • Riviere G, Michaud A, Breton C, VanCamp G, Laborie C, Enache M, Lesage J, Deloof S, Corvol P & Vieau D (2005). Angiotensin-converting enzyme 2 (ACE2) and ACE activities display tissue-specific sensitivity to undernutrition-programmed hypertension in the adult rat. Hypertension 46, 11691174.
  • Rook M, Lely AT, Kramer AB, Van Goor H & Navis G (2005). Individual differences in renal ACE activity in healthy rats predict susceptibility to adriamycin-induced renal damage. Nephrol Dial Transplant 20, 5964.
  • Ruiz-Ortega M, Rupérez M, Esteban V, Rodríguez-Vita J, Sánchez-López E, Carvajal G & Egido J (2006). Angiotensin II: a key factor in the inflammatory and fibrotic response in kidney diseases. Nephrol Dial Transplant 21, 1620.
  • Smith PK, Krohn RI, Hermanson GT, Mallia AK, Gartner FH, Provenzano MD, Fujimoto EK, Goeke NM, Olson BJ & Klenk DC (1985). Measurement of protein using bicinchoninic acid. Anal Biochem 150, 7685.
  • Tikellis C, Cooper ME, Bialkowski K, Johnston CI, Burns WC, Lew RA, Smith AI & Thomas MC (2006). Developmental expression of ACE2 in the SHR kidney: a role in hypertension? Kidney Int 70, 3441.
  • Tikellis C, Johnston CI, Forbes JM, Burns WC, Burrell LM, Risvanis J & Cooper ME (2003). Characterization of renal angiotensin-converting enzyme 2 in diabetic nephropathy. Hypertension 41, 392397.
  • Verhave JC, Hillege HL, Burgerhof JG, Janssen WM, Gansevoort RT, Navis GJ, De Zeeuw D & De Jong PE (2004). Sodium intake affects urinary albumin excretion especially in overweight subjects. J Intern Med 256, 324330.
  • Vogt L, Waanders F, Boomsma F, De Zeeuw D & Navis G (2008). Independent and combined effects of low sodium diet and diuretic on the antiproteinuric efficacy of the AT1-antagonist losartan in non-diabetic proteinuric patients. Clin J Am Soc Nephrol, in press.
  • Wakahara S, Konoshita T, Mizuno S, Motomura M, Aoyama C, Makino Y, Kato N, Koni I & Miyamori I (2007). Synergistic expression of angiotensin-converting enzyme (ACE) and ACE2 in human renal tissue and confounding effects of hypertension on the ACE to ACE2 ratio. Endocrinology 148, 24532457.
  • Wapstra FH, Van Goor H, Navis G, De Jong PE & De Zeeuw D (1996). Antiproteinuric effect predicts renal protection by angiotensin-converting enzyme inhibition in rats with established adriamycin nephrosis. Clin Sci (Lond) 90, 393401.
  • Wolf G & Ritz E (2005). Combination therapy with ACE inhibitors and angiotensin II receptor blockers to halt progression of chronic renal disease: pathophysiology and indications. Kidney Int 67, 799812.
  • Wysocki J, Ye M, Soler MJ, Gurley SB, Xiao HD, Bernstein KE, Coffman TM, Chen S & Batlle D (2006). ACE and ACE2 activity in diabetic mice. Diabetes 55, 21322139.
  • Yagil Y & Yagil C (2003). Hypothesis: ACE2 modulates blood pressure in the mammalian organism. Hypertension 41, 871873.
  • Yamada K, Iyer SN, Chappell MC, Ganten D & Ferrario CM (1998). Converting enzyme determines plasma clearance of angiotensin-(1–7). Hypertension 32, 496502.
  • Ye M, Wysocki J, Naaz P, Salabat MR, LaPointe MS & Batlle D (2004). Increased ACE 2 and decreased ACE protein in renal tubules from diabetic mice. A renoprotective combination? Hypertension 43, 11201125.